Related references
Note: Only part of the references are listed.Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients
Irene A. Abela et al.
CLINICAL INFECTIOUS DISEASES (2020)
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Andrew N. Phillips et al.
LANCET HIV (2020)
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel
Huldrych F. Gunthard et al.
CLINICAL INFECTIOUS DISEASES (2019)
A systematic review of the genetic mechanisms of dolutegravir resistance
Soo-Yon Rhee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1
A. Ayouba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Management of Virologic Failure and HIV Drug Resistance
Suzanne M. McCluskey et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
Dionne M. Hines et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen
Charlotte Charpentier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient
Kara S. McGee et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom
A. Tostevin et al.
HIV MEDICINE (2017)
Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013
A. Zoufaly et al.
INFECTION (2017)
Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection
J. Ambrosioni et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)
Rima Kulkarni et al.
HIV CLINICAL TRIALS (2017)
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
Michael E. Abram et al.
PLOS ONE (2017)
Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
Jose Antonio Mata-Marin et al.
DRUGS IN R&D (2017)
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Catherine Orrell et al.
LANCET HIV (2017)
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Alexandra U. Scherrer et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality
Tracy R. Glass et al.
AIDS (2015)
Primary resistance to integrase strand-transfer inhibitors in Europe
M. Casadella et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study
Gisela Leierer et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study
Guillaume Gras et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen et al.
LANCET INFECTIOUS DISEASES (2012)
Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy
Benjamin Young et al.
ANTIVIRAL THERAPY (2011)
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
Sarita D. Boyd et al.
ANTIVIRAL THERAPY (2011)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
Linda Wittkop et al.
LANCET INFECTIOUS DISEASES (2011)
Cohort Profile: The Swiss HIV Cohort Study
Franziska Schoeni-Affolter et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2010)
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Signe Fransen et al.
JOURNAL OF VIROLOGY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Share Paper
